Klaria Pharma Holding AB (publ.) (STO:KLAR)

Market Cap	196.78M +189.8%
Revenue (ttm)	100.00K -99.1%
Net Income	-45.95M
EPS	-0.22
Shares Out	245.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,215
Open	0.8010
Previous Close	0.8000
Day's Range	0.7940 - 0.8100
52-Week Range	0.3960 - 1.3300
Beta	1.20
Analysts	n/a
Price Target	1.00 (+25.79%)
Earnings Date	Jun 5, 2026

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercial...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: KLAR

Financial Performance

In 2025, STO:KLAR's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -47.06 million, -1.45% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error